ImmunityBio Acquires Manufacturing Facility in New York

ImmunityBio, a clinical-stage immunotherapy company, has completed its acquisition of the leasehold interest in an ISO Class 5 pharmaceutical manufacturing space in western New York from global pharmaceutical company Athenex.

The new state-of-the-art biotech production facility, located in Dunkirk, NY (Chautauqua County), includes clean rooms for upstream and downstream manufacturing activities, as well as fill and finish and large-scale lyophilization capabilities. The full-scale facility enables ImmunityBio to expand and diversify its existing manufacturing capacity in the U.S. and through its strategic collaborators in Africa.

“We are thrilled to add the Dunkirk manufacturing facility and the talented team running it to our organization,” said Richard Adcock, president and CEO, ImmunityBio. “This facility provides production capacity at a significant scale here in the U.S. and at significantly lower capital cost than building a facility like this from the ground up. It is an important component of our overall strategic growth plan, accelerating our ability to develop, prove, and bring to market our most promising products and therapies in competitive and regulated markets.”